Xiang Li

Jan 10, 2025 | nature.com | Xiang Li

AbstractThis paper uses data from the China Health and Nutrition Survey (CHNS) to study the impact of market integration on residents’ health. The empirical results based on the probit model show that market integration has a significant dampening effect on resident incidence. For every one-unit increase in the degree of market integration, the probability of residents becoming sick decreases by approximately 1.45%. Moreover, after a series of robustness tests, the conclusion is still valid.

Dec 26, 2024 | cell.com | Zihao Li |Siwen Chen |Sifang Li |Hua Chao |Wenjun Hao |Shuai Zhang | +5 more

Keywordsnovel proteinribosomal RNARNA polymerase Ipluripotency exitliquid-liquid phase separationGet full text accessLog in, subscribe or purchase for full access. References1. Young, R.A.Control of the embryonic stem cell stateCell. 2011; 144:940-9542. Betschinger, J. ∙ Nichols, J. ∙ Dietmann, S. ... Exit from pluripotency is gated by intracellular redistribution of the bHLH transcription factor Tfe3Cell. 2013; 153:335-3473. Li, M.

Dec 24, 2024 | mdpi.com | Xiang Li

1. IntroductionAgainst the backdrop of carbon emissions peak and carbon neutrality, the new initiative of reduction in pollution and carbon emissions has been strongly supported and highly advocated in China [1]. The quest for clean energy to mitigate carbon emissions is imperative. As a zero-carbon carrier, hydrogen has the advantages of cleanliness and high energy density [2].

Nov 10, 2024 | mdpi.com | Hao Zhang |Zheng Ma |Xiang Li

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Oct 24, 2024 | virologyj.biomedcentral.com | Haidi Wu |Jiaxin Tian |Wenbo Shi |Zhi Ye Wang |Yanjun Du |Hongwei Xu | +8 more

In this observational, real-world study, patients who received tixagevimab/cilgavimab from July 9, 2022, to December 30, 2022, in Hainan, China, were included. The inclusion criteria were patients who received tixagevimab/cilgavimab either before the initiation of the study or were prescribed with tixagevimab/cilgavimab thereafter. The patients participating in interventional clinical trials for SARS-CoV-2 prophylactics or treatments were excluded.